依达拉奉对脑梗死患者尿激酶溶栓后血清C-反应蛋白的影响

目的研究依达拉奉对脑梗死患者尿激酶溶栓后血清C．反应蛋白（CRP）水平的影响，探讨依达拉奉对溶栓后脑组织的保护作用。方法选取脑梗死患者41例随机分为两组，其中观察组19例，对照组22例。对照组给予尿激酶溶栓治疗，观察组在溶栓基础上给予依达拉奉静脉输入，每天2次，共用14d。治疗前后评估临床疗效和神经功能缺损积分，同时用免疫比浊法测定两组患者的血清CRP水平。结果治疗组神经功能缺损积分优于对照组（P〈0．05），总有效率明显高于对照组（P〈0．01），CRP水平较对照组明显降低（P〈0．05）。结论依达拉奉能明显改善急性脑梗死尿激酶溶栓的临床疗效，降低血清CRP水平，对脑梗死病情恢复和预后具有重要意义，依达拉奉可显著改善急性脑梗死患者的神经功能，保护缺血脑组织免受溶栓后代谢毒物的进一步损害。

Effect of edaravone on serum CRP in patients with cerebral infarction after thrombolytic therapy

Objective To investigate the therapeutic effect and the level of C-reactive protein of Edaravone on acute cerebral infarction after thrombolytic therapy in urokinase,and to discuss edaravone on brain tissue protective effect of thrombolytic. Methods 41 patients with cerebral infarction were,divided into 2 groups randomly:treatment group(19cases) and control group(22 cases). Control group received thrombolytic therapy,and treatment group was treated with Edaravone at a dose of 30mg,twice a day,for 14 days. Clinical outcomes and neurological deficit score were evaluated before and after treatment. At the same time, serum CRP levels in patients were determend by immune turbidimetry. Results The treatment group whose neurological deficit score better than the control group ( P ＜ 0.05),the total effective rate was significantly higher( P ＜ 0.01 ) ,compared with the control group, the treatment group CRP levels were significantly lower ( P ＜ 0. 05 ). ConclusionEdaravone on acute cerebral infarction in patients after thrombolysis can significantly improve the clinical efficacy, reduce serum CRP levels, recovery and prognosis of cerebral infarction is important, Edaravone can significantly improve neurological function in patients with acute cerebral infarction,protects against cerebral ischemia after thrombolysis in metabolic poisons further damage.